US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioAge Labs Inc.

4.19

+0.05001.21%

Post-market: 4.190.00000.00%16:05 EDT

Volume:409.80K

Turnover:1.72M

Market Cap:150.21M

PE:-0.63

High:4.27

Open:4.16

Low:4.16

Close:4.14

Loading ...

Overview Company News Filings

Top Premarket Decliners

MT Newswires Live

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

Bioage Labs Inc : Citigroup Cuts to Neutral From Buy

THOMSON REUTERS

Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45

MT Newswires Live

BioAge Shares Slide Premarket After Obesity Study Halted for Safety

BUZZ-Jefferies cuts PT on BioAge after obesity drug trial halted

BioAge Labs downgraded to Hold from Buy at Jefferies

Bioage Labs Shares Down 67.2% Premarket After Co Discontinues Mid-Stage Trial of Experimental Obesity Drug

THOMSON REUTERS

Bioage Labs Inc : Jefferies Cuts to Hold From Buy

THOMSON REUTERS

BUZZ-BioAge Labs tumbles on scrapping mid-stage trial of experimental obesity drug

BioAge Labs Discontinues Clinical Trial for Obesity Treatment

BioAge Labs Terminates Phase 2 Trial of Obesity Drug Candidate

MT Newswires Live

BIOAGE Labs Inc trading resumes

BioAge discontinues mid-stage trial of obesity drug

BRIEF-Bioage Labs Announces Discontinuation Of Strides Phase 2 Clinical Trial

BioAge Labs discontinues STRIDES phase 2 clinical trial

Bioage Labs Inc - Dosing Discontinued, No Additional Subjects to Be Enrolled

THOMSON REUTERS

Bioage Labs Inc - No Transaminase Elevations in Tirzepatide Only Group

THOMSON REUTERS

Bioage Labs Inc - Decision Follows Observations of Liver Transaminitis Without Clinically Significant Symptoms in Some Subjects on Azelaprag

THOMSON REUTERS

Bioage Labs Announces Discontinuation of Strides Phase 2 Clinical Trial Evaluating Azelaprag in Combination With Tirzepatide for the Treatment of Obesity

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BIOA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIOA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":4.19,"timestamp":1746216000000,"preClose":4.14,"halted":0,"volume":409796,"hourTrading":{"tag":"盘后","latestPrice":4.19,"preClose":4.19,"latestTime":"16:05 EDT","volume":394,"amount":1650.86,"timestamp":1746216312673},"delay":0,"floatShares":23809389,"shares":35850037,"eps":-6.629269,"marketStatus":"Market Closed","change":0.05,"latestTime":"05-02 16:00:00 EDT","open":4.16,"high":4.27,"low":4.16,"amount":1724900.6608,"amplitude":0.02657,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.629269,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":4.14,"postHourTrading":{"tag":"盘后","latestPrice":4.19,"preClose":4.19,"latestTime":"16:05 EDT","volume":394,"amount":1650.86,"timestamp":1746216312673},"volumeRatio":1.4261532177619143,"impliedVol":0.9044,"impliedVolPercentile":0.7679},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","floatShares":23809389,"roa":"-25.44%","roe":"-50.35%","lyrEps":-6.629269,"volumeRatio":1.4261532177619143,"shares":35850037,"dividePrice":0,"high":4.27,"amplitude":0.02657,"preClose":4.14,"low":4.16,"week52Low":2.88,"pbRate":"0.46","week52High":26.62,"institutionHeld":0,"latestPrice":4.19,"eps":-6.629269,"divideRate":0,"volume":409796,"delay":0,"ttmEps":-6.629269,"open":4.16,"prevYearClose":5.79,"prevWeekClose":4.23,"prevMonthClose":4.2,"prevQuarterClose":3.76,"fiveDayClose":4.23,"twentyDayClose":3.4,"sixtyDayClose":4.62},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIOA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490721344","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2490721344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490721344?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:41","pubTimestamp":1733748106,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) shares slumped 70% pre-bell Monday after the company said late Friday it is terminating a phase 2 trial of its obesity drug candidate following observations of liver transaminitis.U","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RADX","UPC","FORR","BK4135","BK4123","BIOA","BK4139","BK4007","PSBD","IE00B19Z6F94.USD"],"gpt_icon":1},{"id":"2490724663","title":"Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2490724663","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490724663?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:41","pubTimestamp":1733748082,"startTime":"0","endTime":"0","summary":"On Friday, BioAge LabsInc.  announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.STRIDES was being conducted in collaboration with Eli Lilly And Co’s  Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025.The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.STRIDES is a Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide that planned to enroll approximately 220 individuals with obesity aged 55 years and older.Tirzepatide is an active ingredient of Eli Lilly’s popular Zepbound and Mounjaro.The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag  in combination with tirzepatide .An azelaprag monotherapy arm was included to provide additional safety informati","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Wa2Jh3AkSjLv5nO3T1YH4A--~B/aD0yODE7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a2caea8ec66bfba10e247cae98d4bd2e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Wa2Jh3AkSjLv5nO3T1YH4A--~B/aD0yODE7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a2caea8ec66bfba10e247cae98d4bd2e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/just-two-months-ipo-bioage-124122071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GB00BDT5M118.USD","LU0203201768.USD","BK4533","LU2023250504.SGD","BK4516","LU2089984988.USD","IE0002141913.USD","SG9999014898.SGD","SG9999014880.SGD","LU0122379950.USD","IE00B1BXHZ80.USD","LU2211815571.USD","LU2237443465.HKD","LU2324357040.USD","SG9999015978.USD","LU0672654240.SGD","LU0079474960.USD","BK4585","LU2491049909.HKD","LU0109391861.USD","LU1093756325.SGD","LU2237443382.USD","IE00BK4W5M84.HKD","LU2361044865.SGD","SGXZ99366536.SGD","LU1061106388.HKD","SG9999015986.USD","SGXZ57979304.SGD","LU2237443622.USD","SG9999013999.USD","LU1868837300.USD","BIOA","LU1035775433.USD","LU1712237335.SGD","LU1064131342.USD","LU1127390331.HKD","LU0094547139.USD","LU0456855351.SGD","BK4599","LU0471298777.SGD","IE00BJLML261.HKD","LU0708995401.HKD","LU0882574055.USD","LU1868836914.USD","LU2491050071.SGD","LU1974910355.USD","LU1057294990.SGD","SG9999018857.SGD","LLY","LU2106854487.HKD"],"gpt_icon":1},{"id":"2490772970","title":"Bioage Labs Inc : Citigroup Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490772970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490772970?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:38","pubTimestamp":1733747884,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA17G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2490729396","title":"Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2490729396","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490729396?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:28","pubTimestamp":1733747332,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) has an average rating of overweight and mean price target of $30.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"gpt_icon":0},{"id":"2490282157","title":"BioAge Shares Slide Premarket After Obesity Study Halted for Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2490282157","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490282157?lang=en_us&edition=fundamental","pubTime":"2024-12-09 19:28","pubTimestamp":1733743680,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity drug, due to safety concerns.After the closing bell on Friday, BioAge said it is discontinuing a Phase 2 study of azelaprag after some participants developed liver transaminitis, a condition where the levels of liver enzymes in the blood are higher than normal.The Richmond, Calif., company said it is assessing its next steps for the azelaprag program, adding that it will continue to advance its earlier-stage programs.On the heels of the news, Citi downgraded BioAge's shares to neutral from buy and slashed its price target on the stock to $7 from $45.In a research note, Citi analysts Samantha Semenkow and Geoff Meacham said they believe the liver signal limits azelaprag's path forward in obesity, and that they see limited near-term upside for the stock.However, Citi said BioAge's pipeline, dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2490747955","title":"BUZZ-Jefferies cuts PT on BioAge after obesity drug trial halted","url":"https://stock-news.laohu8.com/highlight/detail?id=2490747955","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490747955?lang=en_us&edition=fundamental","pubTime":"2024-12-09 18:51","pubTimestamp":1733741480,"startTime":"0","endTime":"0","summary":"** Shares of drug developer BioAge Labs    down ~70% to $6.13 premarket   ** Brokerage Jefferies downgrades stock to \"hold\" from \"buy\"; lowers PT to $7 from $42   ** New PT represents a 65.2% downside to Friday's close of $20.09   ** Brokerage lowers PT on discontinuation of co's mid-stage obesity drug trial due to liver safety concerns   ** Brokerage expects significant \"stock drop\"   ** Brokerage also lowers co's drug pipeline value to $200 mln from $300 mln   ** As of last close, stock has fallen 10.7% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4166","PT","BK4007"],"gpt_icon":0},{"id":"2490742415","title":"BioAge Labs downgraded to Hold from Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2490742415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490742415?lang=en_us&edition=fundamental","pubTime":"2024-12-09 18:30","pubTimestamp":1733740236,"startTime":"0","endTime":"0","summary":"Jefferies downgraded BioAge Labs (BIOA) to Hold from Buy with a price target of $7, down from $42. The company discontinued the Phase 2 obesity stu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-downgraded-to-hold-from-buy-at-jefferies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-downgraded-to-hold-from-buy-at-jefferies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA"],"gpt_icon":0},{"id":"2490745029","title":"Bioage Labs Shares Down 67.2% Premarket After Co Discontinues Mid-Stage Trial of Experimental Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490745029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490745029?lang=en_us&edition=fundamental","pubTime":"2024-12-09 17:15","pubTimestamp":1733735721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4N3NA0KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2490748506","title":"Bioage Labs Inc : Jefferies Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490748506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490748506?lang=en_us&edition=fundamental","pubTime":"2024-12-09 16:28","pubTimestamp":1733732892,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2489052260","title":"BUZZ-BioAge Labs tumbles on scrapping mid-stage trial of experimental obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2489052260","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489052260?lang=en_us&edition=fundamental","pubTime":"2024-12-07 07:04","pubTimestamp":1733526289,"startTime":"0","endTime":"0","summary":"** Shares of drug developer BioAge Labs    crater 67.6% to $6.52 in extended trading   ** Co discontinues mid-stage trial of its experimental obesity drug after high levels of certain liver enzymes observed in some patients   ** BioAge's experimental drug, azelaprag, mimics activity of the exerkine apelin, a peptide released in response to exercise due to muscle contraction   ** Co was studying azelaprag as a monotherapy and in combination with Eli Lilly's    tirzepatide   ** BioAge has stopped dosing all patients and plans to further analyze data from people who have been enrolled   ** As of last close, stock down ~10% since its market debut in September ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BUZZ-BioAge Labs tumbles on scrapping mid-stage trial of experimental obesity drug","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2489243262","title":"BioAge Labs Discontinues Clinical Trial for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2489243262","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489243262?lang=en_us&edition=fundamental","pubTime":"2024-12-07 06:15","pubTimestamp":1733523300,"startTime":"0","endTime":"0","summary":"BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity.The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis.No transaminase elevations were observed in the tirzepatide only treatment group, the company added.\"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile,\" Chief Executive Kristen Fortney said.The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2489262959","title":"BioAge Labs Terminates Phase 2 Trial of Obesity Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2489262959","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489262959?lang=en_us&edition=fundamental","pubTime":"2024-12-07 06:08","pubTimestamp":1733522912,"startTime":"0","endTime":"0","summary":"BioAge Labs  said late Friday it is terminating its phase 2 study of the investigational drug candidate azelaprag as both monotherapy and in combination with tirzepatide following observations of liver transaminitis in some subjects, without clinically significant symptoms.The company also noted that no transaminase elevations were detected in the tirzepatide-only treatment group.BioAge had planned to enroll approximately 220 individuals aged 55 years and older for the trial.BioAge Chief Executive Kristen Fortney said that the difficult decision was made to discontinue the  Phase 2 study of azelaprag as the emerging safety profile of the current doses tested was not consistent with the company's goal of a best-in-class oral obesity therapy.\"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile,\" Fortney said.Trading of shares of BioAge was halted and set to resume later Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2489262275","title":"BIOAGE Labs Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2489262275","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489262275?lang=en_us&edition=fundamental","pubTime":"2024-12-07 06:00","pubTimestamp":1733522429,"startTime":"0","endTime":"0","summary":"17:00 EST BIOAGE Labs (BIOA) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2489264338","title":"BioAge discontinues mid-stage trial of obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2489264338","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489264338?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:43","pubTimestamp":1733521410,"startTime":"0","endTime":"0","summary":"Dec 6  - BioAge Labs    said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's  tirzepatide for the treatment of obesity. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0820561818.USD","BIOA","LU1093756325.SGD","LU2237443895.HKD","LLY","LU0823416689.USD","LU1623119135.USD","LU0061475181.USD","LU0466842654.USD","IE00BFTCPJ56.SGD","LU2491049909.HKD","SG9999013999.USD","BK4534","SG9999014914.USD","LU1127390331.HKD","SG9999015978.USD","LU0672654240.SGD","LU0689472784.USD","LU0882574139.USD","LU1868836757.USD","SG9999015952.SGD","SGXZ31699556.SGD","LU1868836591.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0097036916.USD","LU0096364046.USD","SG9999018857.SGD","LU1974910355.USD","LU1291159041.SGD","IE00BJLML261.HKD","LU0471298777.SGD","LU1814569148.SGD","LU0109391861.USD","LU2211815571.USD","SG9999015986.USD","LU2491050071.SGD","SGXZ51526630.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","BK4599","LU0256863902.USD","LU1917777945.USD","LU2491050154.USD","LU0203201768.USD","LU2106854487.HKD","IE0004445239.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2489264885","title":"BRIEF-Bioage Labs Announces Discontinuation Of Strides Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2489264885","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489264885?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:40","pubTimestamp":1733521255,"startTime":"0","endTime":"0","summary":"BRIEF-Bioage Labs Announces Discontinuation Of Strides Phase 2 Clinical TrialDec 6 (Reuters) - BIOAGE Labs Inc BIOA.O:BIOAGE LABS ANNOUNCES DISCONTINUATION OF STRIDES PHASE 2 CLINICAL TRIAL EVALUATING","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nTUABRNBGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2489060264","title":"BioAge Labs discontinues STRIDES phase 2 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2489060264","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489060264?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:40","pubTimestamp":1733521209,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) announced that the company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-discontinues-strides-phase-2-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-discontinues-strides-phase-2-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2489614162","title":"Bioage Labs Inc - Dosing Discontinued, No Additional Subjects to Be Enrolled","url":"https://stock-news.laohu8.com/highlight/detail?id=2489614162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489614162?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:35","pubTimestamp":1733520919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nTUABRNBGV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2489426141","title":"Bioage Labs Inc - No Transaminase Elevations in Tirzepatide Only Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2489426141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489426141?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:35","pubTimestamp":1733520919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nTUABRNBGV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2489411261","title":"Bioage Labs Inc - Decision Follows Observations of Liver Transaminitis Without Clinically Significant Symptoms in Some Subjects on Azelaprag","url":"https://stock-news.laohu8.com/highlight/detail?id=2489411261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489411261?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:35","pubTimestamp":1733520919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nTUABRNBGV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2489261419","title":"Bioage Labs Announces Discontinuation of Strides Phase 2 Clinical Trial Evaluating Azelaprag in Combination With Tirzepatide for the Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2489261419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489261419?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:35","pubTimestamp":1733520919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nTUABRNBGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":70,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIOA\",params:#limit:5,,,undefined,":[{"date":"2025-03-20","symbol":"BIOA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":-0.58,"defaultRemindTime":1742500800000,"name":null,"time":"Post Market","dateTimestamp":1742443200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIOA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIOA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.75,"sell":0.25,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":4,"updateTime":1740715200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BIOA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BIOA","date":"2025-05-02","current":-2.087206,"percent":0.865772,"low":-14.88445,"twenty":-10.498085,"median":-2.486337,"eighty":-2.155781,"high":-1.532635,"avg":-5.439558,"sd":4.477913,"marketCap":148419153},"quantilePoints":[{"date":"2024-09-27","current":-10.065016,"twenty":-9.996853,"median":-9.894609,"eighty":-9.328936,"marketCap":625601139},{"date":"2024-10-04","current":-11.466752,"twenty":-11.453559,"median":-10.988513,"eighty":-9.962772,"marketCap":712727458},{"date":"2024-10-11","current":-11.290848,"twenty":-11.83725,"median":-11.290848,"eighty":-10.377246,"marketCap":701793959},{"date":"2024-10-18","current":-13.247909,"twenty":-12.852074,"median":-11.505231,"eighty":-10.913754,"marketCap":823437060},{"date":"2024-10-25","current":-13.708907,"twenty":-13.699687,"median":-12.032944,"eighty":-11.062173,"marketCap":852090807},{"date":"2024-10-31","current":-14.198716,"twenty":-13.910593,"median":-12.258321,"eighty":-11.163318,"marketCap":882535413},{"date":"2024-11-08","current":-10.411209,"twenty":-13.841443,"median":-12.631325,"eighty":-11.163318,"marketCap":738550334},{"date":"2024-11-15","current":-9.850761,"twenty":-13.741177,"median":-12.203351,"eighty":-10.879672,"marketCap":698793259},{"date":"2024-11-22","current":-9.318711,"twenty":-13.704297,"median":-11.736106,"eighty":-10.071646,"marketCap":661050728},{"date":"2024-11-29","current":-9.500638,"twenty":-13.685857,"median":-11.456511,"eighty":-9.850761,"marketCap":673956274},{"date":"2024-12-06","current":-9.283336,"twenty":-13.657045,"median":-11.290848,"eighty":-9.500638,"marketCap":658541317},{"date":"2024-12-13","current":-2.319571,"twenty":-13.258776,"median":-11.073716,"eighty":-9.298497,"marketCap":164545707},{"date":"2024-12-20","current":-2.612676,"twenty":-13.247909,"median":-10.411209,"eighty":-9.141838,"marketCap":185337975},{"date":"2024-12-27","current":-2.971476,"twenty":-13.224859,"median":-10.152544,"eighty":-7.606575,"marketCap":210790579},{"date":"2025-01-03","current":-2.809763,"twenty":-13.09117,"median":-10.065016,"eighty":-3.032119,"marketCap":199318983},{"date":"2025-01-10","current":-2.572247,"twenty":-12.858367,"median":-9.894609,"eighty":-2.886577,"marketCap":182470076},{"date":"2025-01-17","current":-2.54698,"twenty":-12.632478,"median":-9.680039,"eighty":-2.714757,"marketCap":180677639},{"date":"2025-01-24","current":-2.678371,"twenty":-12.552115,"median":-9.568861,"eighty":-2.625815,"marketCap":189998311},{"date":"2025-01-31","current":-2.415588,"twenty":-12.247327,"median":-9.318711,"eighty":-2.600547,"marketCap":171356967},{"date":"2025-02-07","current":-2.309464,"twenty":-12.16927,"median":-9.263122,"eighty":-2.51868,"marketCap":163828732},{"date":"2025-02-14","current":-2.284196,"twenty":-12.012055,"median":-9.141838,"eighty":-2.417609,"marketCap":162036295},{"date":"2025-02-21","current":-2.223554,"twenty":-11.928501,"median":-8.818412,"eighty":-2.37516,"marketCap":157734447},{"date":"2025-02-28","current":-2.208393,"twenty":-11.54371,"median":-3.087708,"eighty":-2.319571,"marketCap":156658985},{"date":"2025-03-07","current":-2.269035,"twenty":-11.466752,"median":-2.971476,"eighty":-2.294303,"marketCap":160960833},{"date":"2025-03-14","current":-2.122483,"twenty":-11.446271,"median":-2.893147,"eighty":-2.269035,"marketCap":150564699},{"date":"2025-03-21","current":-2.208204,"twenty":-11.43377,"median":-2.779442,"eighty":-2.233661,"marketCap":157023162},{"date":"2025-03-28","current":-1.956126,"twenty":-11.290848,"median":-2.7188,"eighty":-2.233661,"marketCap":139098143},{"date":"2025-04-04","current":-1.714131,"twenty":-11.203915,"median":-2.693532,"eighty":-2.213447,"marketCap":121890125},{"date":"2025-04-11","current":-1.729255,"twenty":-11.131435,"median":-2.645523,"eighty":-2.198286,"marketCap":122965626},{"date":"2025-04-17","current":-1.890585,"twenty":-11.039085,"median":-2.589935,"eighty":-2.192221,"marketCap":134437638},{"date":"2025-04-25","current":-2.117456,"twenty":-10.879672,"median":-2.54698,"eighty":-2.170997,"marketCap":150570155},{"date":"2025-05-02","current":-2.087206,"twenty":-10.498085,"median":-2.486337,"eighty":-2.155781,"marketCap":148419153}],"updateTime":1746321959227}}}